Financial Performance - In 2025, the company achieved a revenue of CNY 38.24 billion, representing a year-on-year growth of 60.25% [3] - The net profit attributable to shareholders reached CNY 10.88 billion, with a year-on-year increase of 107.97% [3] - Total assets amounted to CNY 45.29 billion, while net assets were approximately CNY 31.6 billion, resulting in a debt-to-asset ratio of about 30% [3] - The company maintained a healthy operational efficiency with accounts receivable and inventory turnover [3] Market Trends and Product Demand - The demand for AI computing power is rapidly increasing, with a shift from 400G to 800G networks expected in 2025 [5] - The company anticipates an annual production capacity of over 28 million units in 2025, with sales of 21.09 million units, of which 18 million units are targeted for overseas markets [5] - The product mix primarily includes 800G and 400G optical modules, along with a limited number of 1.6T modules [5] - The optical module industry is expected to continue strong demand in 2026, with 1.6T and 800G products becoming the main focus [5] Financial Management and Cost Control - The company reported a significant increase in financial expenses due to exchange losses from the appreciation of the RMB, which are primarily paper losses [3] - Strategies to manage exchange rate risks include short-term settlements and forward product combinations [6] - The company has increased procurement efforts and signed supply agreements to mitigate material shortages caused by rapid downstream demand growth [7] Gross Margin and Profitability Outlook - The overall gross margin for the year is expected to remain stable with a slight upward trend, following a record high in Q4 2025 [9] - Factors influencing gross margin fluctuations in Q1 2026 include price adjustments and material cost responses [9] Future Capacity and Investment Plans - The company plans to further increase production capacity in 2026 to meet customer orders and market demand [11] - Continued investment in R&D is expected, focusing on new technologies and product development [11] Industry Insights and Competitive Position - The company maintains a strong market share in 800G and 1.6T segments, with no significant changes in the competitive landscape among major clients [15] - The scale-across optical modules are anticipated to address interconnect needs between AI computing clusters, indicating a fast-growing market opportunity [12]

Group 1: Financial Performance - In 2025, the company achieved a revenue of 9.51 billion yuan, a year-on-year increase of 26.13% [3] - The net profit attributable to shareholders reached 1.14 billion yuan, growing by 63.35% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 1.10 billion yuan, reflecting a 74.59% increase [3] - The main growth driver was the domestic business, which generated 7.20 billion yuan, up 37.76% year-on-year [3] Group 2: Sales Channels and Product Performance - Direct sales channels grew by 40.12%, while the distribution channels also maintained rapid growth, with JD's distribution increasing by 41.53% and gift channels by 88.84% [3] - The company’s product categories, including steam pots, health pots, multifunctional pots, and cooking utensils, contributed significantly to revenue growth [3] - The overseas business revenue from self-owned brands decreased by 8.23% due to a strategic focus on profitability and the contraction of low-efficiency areas [3] Group 3: Operational Strategies - The company emphasized cost reduction and efficiency improvement, which positively impacted profit margins [3] - The business model for overseas brand operations has shifted to a distribution model, which, despite affecting revenue recognition, has improved cash flow and profitability [3] - The company plans to balance revenue growth and profit margin enhancement, with a focus on long-term product development and strategic resource allocation [7] Group 4: Market and Policy Insights - The impact of national consumption stimulus policies exceeded expectations, while the negative effects of the US-China trade war were less severe than anticipated [3] - The company does not rely on short-term policy factors for product strategy but focuses on long-term research and development planning [4] - The company is cautious about expanding into Southeast Asia due to limited mid-to-high-end consumer markets and significant product specification differences [9]

Group 1: Business Overview - In 2025, the total business volume reached 16.7 billion parcels, a year-on-year increase of 25.4%, significantly exceeding the industry average growth rate [3] - Revenue reached 308.2 billion yuan, up 8.4% year-on-year, with express logistics revenue at 228.6 billion yuan, growing 11.1% [3] - The supply chain and international revenue reached 72.9 billion yuan, a 3.5% increase, with supply chain and international (excluding KLN) revenue growing by 32.3% [3] Group 2: Operational Efficiency - The company achieved a net profit of 11.1 billion yuan, a year-on-year increase of 9.3%, with a net profit margin of 3.6% [3] - The weighted average return on equity was 11.5%, an increase of 0.35 percentage points year-on-year [3] - The company implemented strategic investments to enhance long-term competitiveness and dynamically adjusted its business structure to improve operational efficiency [3] Group 3: Service Segments - Express delivery revenue grew by 7.2%, outperforming domestic GDP growth, driven by targeted investments in diverse scenarios [4] - Economic express revenue increased by 17.6%, leveraging a "first have, then optimize" strategy for resource and product matching [5] - Fast delivery revenue rose by 11.9%, with a cargo volume increase of over 27%, maintaining a leading position in both scale and growth [6] Group 4: Supply Chain and International Business - Supply chain and international revenue (excluding KLN) grew by 32.3%, with a net profit of approximately 190 million yuan, an increase of 950 million yuan year-on-year [8] - The company developed three core capabilities to navigate international changes, including end-to-end supply chain support and agile international express services [8] - The company operates nearly 2.55 million square meters of overseas warehouses, with 2.1 million square meters in the Asia-Pacific region, leading the market [9] Group 5: Financial Performance - In Q4 2025, business volume reached 4.6 billion parcels, a year-on-year increase of 18.3%, with revenue of 83 billion yuan, up 7.0% [17] - The gross profit for 2025 was 41 billion yuan, a 3.6% increase, with a gross margin of 13.3% [19] - The company maintained a healthy capital structure with a debt-to-asset ratio of 49% and a free cash flow of 17.9 billion yuan [23] Group 6: Shareholder Returns - The company maintained a dividend payout ratio of 40%, distributing a total of 4.46 billion yuan in dividends, a 9% increase year-on-year [24] - The company has repurchased shares worth over 7 billion yuan since 2022, with plans to increase the repurchase amount to 3-6 billion yuan for A-shares [25] Group 7: ESG Initiatives - The company is committed to sustainable development, aiming for net-zero emissions by 2050, and has established a carbon management platform [26] - The company's ESG practices have received high recognition, with an MSCI ESG rating upgrade from "A" to "AA" [27]

Group 1: Market Potential - The domestic market for frozen noodles is estimated to reach a scale of 100 billion RMB, with the current market capacity at around 2-3 billion RMB [2][3]. Group 2: Competitive Advantages of Asia Plus - Asia Plus is a well-established brand in the Chinese frozen noodle industry, particularly strong in the B-end market with a high customer loyalty and premium pricing capability [3]. - The B-end sales channel accounts for 90% of Asia Plus's sales, with leading market shares in Japanese, Western, and some Chinese dining channels [3]. Group 3: Product Quality and Technology - Asia Plus has a high starting point in core production processes, supported by 30 years of production experience, creating a systematic technological barrier in product quality and stability [3]. - The acquisition of Asia Plus will allow the company to leverage its technology and experience for the Jiaxing frozen noodle project [3]. Group 4: Clientele and Market Strategy - Major clients of Asia Plus include He Fu Noodle, Pizza Hut Hong Kong, and Domino's Pizza [4]. - The company plans to integrate its high-end products into Asia Plus's restaurant chain channels while expanding Asia Plus's products into the C-end market through its existing distribution network [5]. Group 5: Operational Strategy Post-Acquisition - After the acquisition, Asia Plus will operate independently, retaining its core team, with Yang Bo as the general manager overseeing management and resource integration [5]. - The current production capacity utilization of Asia Plus is at 100%, and the acquisition will facilitate the expansion of frozen noodle production at the Jiaxing factory [7]. Group 6: Strategic Focus - The company will focus on frozen noodles as a core strategy, avoiding competition in traditional rice and dumpling markets, and will initially target B-end business before gradually expanding to C-end [7]. - The trend of increasing consumer demand for the taste and convenience of noodles supports the long-term growth of frozen noodles [7].

Group 1: Investor Relations Activities - The company engaged in various investor relations activities, including analyst meetings, media interviews, performance briefings, and roadshows, with participation from 110 institutional investors [1] - The activities took place from March 25 to March 30, 2026, in Shanghai and online [3] Group 2: Company Development and AI Strategy - The company aims to embrace AI and capitalize on the opportunities presented by AI computing power technology and data center upgrades, targeting a production value of 100 billion by 2030 [3][4] - High-end products in AI-related fields have achieved large-scale production, significantly increasing the proportion of high-value, high-technical-complexity products [3] Group 3: Production Capacity and Expansion - The company is actively expanding production capacity, with domestic facilities in Huizhou gradually entering production phases, while overseas facilities in Thailand and Vietnam are also progressing as planned [4][5] - The priority for capacity construction has shifted to domestic installations due to changes in customer demand and resource availability [4] Group 4: Order Visibility and Customer Development - The order visibility in the PCB industry typically spans around two months, with high-end products having longer visibility [5] - The company is optimizing its customer structure and making progress in the AI sector, which is expected to drive future growth [5] Group 5: Raw Material Costs and Pricing Stability - The company has established stable relationships with key raw material suppliers, ensuring a steady supply [6][7] - Despite potential fluctuations in raw material prices, the company maintains stable pricing for high-end products due to effective cost management strategies [7] Group 6: Future Market Trends and Capacity Needs - The demand for high-end PCBs is expected to grow due to increasing signal transmission bandwidth and material standards, leading to a tighter supply situation [8] - The company is expanding its capabilities to meet the rising demand for AI computing and servers, which will support sustained industry growth [8] Group 7: Hong Kong Listing Progress - The company is actively working on its Hong Kong listing, collaborating closely with intermediaries to ensure timely progress [9] Group 8: Acquisition of SunPower - The acquisition of SunPower aims to enhance production capacity in Southeast Asia and improve global supply capabilities, facilitating faster customer delivery [10][11]

Group 1: Company Performance and Outlook - The company expects stable order growth in 2026, following a positive performance in 2025 [2] - The gross profit margin for the first half of 2025 is reported at 42%, influenced by product prices and costs [2][3] - The company aims to enhance gross margin through R&D innovation, improving product quality, and reducing inventory [3] Group 2: Project Developments - The Jiangsu Gaoxin chip project is progressing, with new product lines and facilities under installation, aiming for production commencement soon [4] - The company is increasing customer reserves for its 6-8 inch polished wafer project, focusing on power devices and integrated circuits [6] Group 3: Production and Market Strategy - Production plans are dynamically adjusted based on sales orders and market forecasts, ensuring capacity meets customer demands [7] - The company is responding to fluctuating market demands by optimizing product quality and expanding customer relationships [8][9] - Current production pace is tight, with plans to recruit and train staff to ensure timely delivery of products [9] Group 4: Raw Material Management - The company monitors raw material price fluctuations and collaborates with suppliers to mitigate impacts on operations [5] Group 5: Pricing Strategy - Product pricing is influenced by market supply and demand, with current prices for standard products remaining stable [9]

Financial Performance - In 2025, the company achieved operating revenue of CNY 1.886 billion, a year-on-year increase of 20.93% [3] - The net profit attributable to shareholders was CNY 68.54 million, a decrease of 40.62%, primarily due to adjustments related to the acquisition of Saint Nor [3] - Excluding non-recurring items, the net profit attributable to shareholders increased by 28.50% to CNY 107 million [3] - The net cash flow from operating activities was CNY 341 million, up 31.47% year-on-year [3] Medical Services - The medical services segment generated revenue of CNY 1.501 billion, with a patient volume of 604,100, reflecting an 11% year-on-year growth [4] - Surgical volume increased by 71%, with advanced surgeries (level 3 and 4) accounting for 78% of total surgeries, up 7 percentage points [4] - The company completed a strategic acquisition of Changsha Kexin Tumor Hospital, contributing CNY 622 million to tumor business revenue, which represented 41.5% of medical service income [3][4] Technological Innovation - The company has integrated AI capabilities into key diagnostic and treatment processes, reducing preoperative planning time by approximately 80% and decreasing postoperative hospital stays by 1.5 days [7] - AI-enabled services have achieved a patient Net Promoter Score (NPS) of 93%, surpassing the industry average of 90% [7] Medical Devices - The medical device segment reported revenue of CNY 380 million, a year-on-year increase of 14.30% [9] - The acquisition of Saint Nor and Uni Medical exceeded performance targets, with Saint Nor achieving a net profit of CNY 87.40 million, a completion rate of 127.47% for performance commitments [10] - The overseas revenue for medical devices reached CNY 104 million, up 20.24% year-on-year [10] Strategic Development - The company plans to continue expanding its regional medical center layout and pursue "ecological mergers" to enhance synergy [20] - Focus areas for future acquisitions include imaging enhancement, tumor treatment, life support, and blood circulation [20] - The company is also developing a comprehensive health management platform for cancer patients, which is currently in the testing phase [12]

Financial Performance - The company achieved a revenue of CNY 2.741 billion, a year-on-year decrease of 4.46% [3] - Net profit attributable to shareholders was CNY 196 million, an increase of 6.42% year-on-year, indicating stable core business operations [3] - The nuclear medicine segment generated sales of CNY 1.136 billion, up 12.21% year-on-year, with key product 18F-FDG contributing CNY 498 million, a growth of 18.35% [3] - The raw material drug segment reported sales of CNY 1.014 billion, down 19.19%, primarily due to a 22.17% decline in heparin product sales [3] - The formulation segment's sales reached CNY 359 million, a growth of 10.37%, with key product nadroparin calcium injection achieving CNY 157 million, up 22.78% [3] R&D Progress - Multiple innovative and generic drugs made significant breakthroughs, with three innovative nuclear drugs entering Phase II clinical trials and one in Phase III [3] - The NDA for 18F-FDG was submitted and accepted by the National Medical Products Administration on January 9, 2026 [3] - The company established a radioactive isotope development platform to address the shortage of medical isotopes, with strategic partnerships for the construction of a dedicated reactor project [5] Production Capacity - The company operates 31 nuclear medicine production centers, covering 93.5% of the domestic nuclear medicine demand [4] - Seven centers are under construction, enhancing the company's competitive edge in networked production [4] Market Strategy - The accessibility of 18F-FDG improved due to the optimized management and service quality, leading to increased sales [8] - The company is focusing on international collaborations to enhance its position in the medical isotope market [7] Future Outlook - The company plans to complete product qualification for 20 production centers by the end of 2026, enhancing its production capabilities [9] - The pricing trend for raw material heparin is expected to remain volatile, influenced by overall industry conditions [12] - The company is actively pursuing overseas business opportunities to leverage international expertise and standards [14]

Group 1: Company Performance - In 2025, the company achieved a revenue of CNY 4.09 billion, an increase of 5.96% compared to the previous year [4] - The net profit attributable to shareholders was CNY 52.89 million, a decrease of 1.65%, but adjusted for stock incentive expenses, the net profit was CNY 71.22 million, an increase of 32.42% [5] - Earnings per share for 2025 was CNY 0.0520 [5] Group 2: Future Projections - The company aims to increase its market share in the robotics sector, with a focus on large clients and expanding its customer base [3] - The RV reducer product line includes over 50 specifications and is expected to continue growing in sales and revenue in 2026 [3] - The company plans to release new products, including high-efficiency CNC internal and external thread grinding machines, in April 2026 [9] Group 3: Market Position and Strategy - The company has established partnerships with leading domestic robot manufacturers, although specific client names are confidential [2] - The high-end industrial mother machine innovation base has successfully developed a product matrix covering over 20 models, enhancing its market presence in key industries [4] - The company is committed to addressing key challenges in high-end machine tools, including high-end CNC systems and precision detection [8] Group 4: Financial Management and Investor Relations - The company has implemented cash dividends and buybacks totaling CNY 82.10 million from 2023 to 2025, emphasizing its commitment to investor returns [8] - The company regularly conducts asset impairment tests and has accounted for CNY 103 million in impairments, ensuring asset quality [7] - Future performance will be closely monitored and reported in quarterly updates, with expectations for growth in the first quarter of 2026 [8]

Group 1: Financial Performance - In 2025, the company achieved a revenue of CNY 5.485 billion, representing a year-on-year growth of 46.89% [3] - The net profit for 2025 was CNY 1.016 billion, with a year-on-year increase of 50.24% [3] - The company’s five largest customers contributed 60.74% of total revenue, with the largest customer accounting for 20.20% [6] Group 2: Production Capacity and Expansion - The production capacity in 2026 is projected to be CNY 1.5 billion for Huangshi, over CNY 1 billion for Thailand, and around CNY 6 billion for Guangzhou [5] - The company is advancing several expansion projects, including upgrades at Guangzhou plants and new construction in Thailand, which are expected to support rapid growth in 2027 [5] - The Thailand facility achieved monthly profitability within six months of its launch in June 2025, indicating strong operational efficiency [5] Group 3: Product Development and Market Strategy - The company focuses on core customers in the computing power sector, enhancing product structure through technological innovation [3] - AI-related products generated approximately CNY 1.2 billion in revenue in 2025, accounting for about 24% of main business revenue [8] - The transition from PCIe 5.0 to PCIe 6.0 is expected to begin in Q3 2026, leading to significant upgrades in product pricing and demand [10] Group 4: Supply Chain and Material Costs - The company is monitoring the impact of rising raw material prices, such as copper and fiberglass, on profitability, but expects limited effects on its core PCB business [7] - Strategies to mitigate cost increases include enhancing communication with suppliers and optimizing product structures [7] Group 5: Customer Base and Market Position - Eight of the top ten global server manufacturers are customers of the company, with a goal to achieve full coverage of these manufacturers in the next three years [6] - The company is preparing to increase market share in GPU products, which are seen as a key area for business expansion [9]